화학공학소재연구정보센터
학회 한국고분자학회
학술대회 2020년 가을 (10/05 ~ 10/08, 부산컨벤션센터(BEXCO))
권호 45권 1호
발표분야 의료용 고분자 부문위원회 II
제목 The Hybrid Hydrogel for Sustained Release and Extended Half-life: Albumin Affibody-Conjugated Injectable Gel with Albumin-Conjugated Urate Oxidase for the Treatment of Hyperuricemia
초록 The short half-life of therapeutic proteins is usually a bottleneck for their clinical application. Injectable hydrogels have been used as depots for the controlled release of therapeutic proteins. However, the native interactions between therapeutic protein and hydrogel are often not sufficient to achieve extended release of the therapeutic protein. Herein, we investigated whether a pair of HSA and its very strong ligand, albumin-binding peptide (ABP), can be used to achieve substantially extended release of therapeutic protein from injectable hydrogel. HSA was conjugated to a therapeutic protein. The ABP was conjugated to pH- and temperature-sensitive poly(ethylene glycol)-poly(β-amino ester urethane) (PEG-PAEU) copolymer. As a result, the serum activity half-life of the Uox-HSA conjugate loaded in the ABP-modified PEG-PAEU hydrogels was 96 h, which was much longer than those of free native Uox, free Uox-HSA, and Uox-HSA conjugate loaded in the unmodified PEG-PAEU hydrogels.
저자 조진환1, 권인찬2
소속 1광주과학기술원, 2신소재공학부
키워드 Extended drug release; Injectable hydrogel; Albumin-binding peptide; Hyperuricemia
E-Mail